Several large-scale clinical trials have corroborated the remarkable efficacy of SGLT-2 inhibitors in reducing the risk of HF hospitalization, cardiovascular mortality, and improving renal outcomes.[14–16] However, due to variations in study populations, design protocols, and follow-up durations, heterogeneity exists among these findings. This evidence concerns the gene SLC5A2 and hydrops fetalis.